BioTuesdays Feature Articles | Life Sciences News

Feature

Rhythm Pharma targeting rare genetic diseases of obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM), with the only FDA-approved therapy that targets a root cause of severe obesity and insatiable hunger, is in clinical development to expand the addressable population of patients...

August 2, 2022

Feature

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Eupraxia Pharmaceuticals (TSX:EPRX) is developing a unique diffusion-based polymer-particle technology initially to provide knee osteoarthritis (OA) patients with an injection in the knee for an extended release of drug...

July 26, 2022

Feature

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

Tonix Pharmaceuticals (NASDAQ:TNXP) is engaged in a number of ongoing and planned clinical trials with a rich pipeline of products, including a Phase 3 clinical trial to treat fibromyalgia, along with a Phase 2 clinical...

July 19, 2022

Feature

TC Biopharm developing gamma-delta T-cells therapies for oncology

TC BioPharm (NASDAQ:TCBP) is a global leader in developing platform allogeneic gamma-delta T-cell therapies for cancer indications, with human efficacy data in acute myeloid leukemia (AML) and plans to expand into other...

July 12, 2022

Feature

Aristea Therapeutics in four clinical trials in rare inflammatory diseases

Closely-held Aristea Therapeutics is pursuing four rare inflammatory diseases with its oral, once-daily, small molecule drug candidate, RIST4721: palmoplantar pustulosis, familial Mediterranean fever, Behcet’s disease...

July 5, 2022

Feature

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

Pharvaris (NASDAQ:PHVS), a trans-Atlantic company, is developing two oral products to treat and prevent attacks in all subtypes of hereditary angioedema (HAE), with on-demand and prophylactic therapies.

June 28, 2022

Feature

NeuroSense advancing potential paradigm shift in ALS therapy

NeuroSense Therapeutics (NASDAQ:NRSN) is developing a novel fixed dose combination of two FDA-approved drugs for a multi-targeted approach against the potential pathways responsible for ALS, or amyotrophic lateral...

June 21, 2022

Feature

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

QSAM Biosciences (OTCQB:QSAM) began dosing bone cancer patients in a Phase 1 study in April 2022 with its next-generation radiopharmaceutical, CycloSam, which delivers the beta-emitting radioisotope, samarium-153, to...

June 14, 2022

Feature

Synlogic advancing novel biotherapeutics based on synthetic biology

Synlogic (NASDAQ:SYBX) is advancing a new class of biotherapeutics, known as Synthetic Biotics, targeting validated biology in rare metabolic and immunological diseases.

June 7, 2022

Feature

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

Closely-held Iterion Therapeutics is employing a unique strategy with its lead asset, tegavivint, which is designed to bind to TBL1 (transducin beta-like protein one) and inhibit nuclear beta-catenin signaling and...

May 31, 2022

Feature

MindMed driving therapeutic potential of psychedelics for brain health disorders

MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.

May 24, 2022

Feature

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Closely-held Lanier Biotherapeutics is pioneering a first-in-class Type 2 and non- Type2 anti-inflammatory biologic, LNR 125, as a new candidate targeting treatments commonly associated with Type 2 inflammation like...

May 17, 2022

Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.

May 10, 2022

Feature

Talking mental health with Chris Wang of Shimmer

As co-founder and CEO of Shimmer, a provider of a science-backed process to reduce stress and anxiety, Chris Wang took an early interest in social impact consulting at her first job with Bain & Co. But a close family...

May 3, 2022

Feature

Claritas Pharmaceuticals transforming nitric oxide therapy

Claritas Pharmaceuticals (TSXV:CLAS; OTC:CLAZF) is developing R-107, a liquid drug candidate that may hold the key to transforming nitric oxide therapy from its current gaseous inhalation method of delivery to...

April 26, 2022

Feature

In conversation with Dr. Murat Kalayoglu of Cartesian

As president and CEO of closely-held Cartesian Therapeutics, Murat Kalayoglu, M.D., Ph.D., has made a smooth transition over the years from a board-certified ophthalmologist to a healthcare IT entrepreneur to a medical...

April 12, 2022

Feature

Cocrystal Pharma advancing programs in high-value antiviral drug targets

With a drug discovery technology platform developed by several Nobel Prize laureates, Cocrystal Pharma (NASDAQ:COCP) is advancing broad spectrum antivirals in three programs: coronaviruses and variants, pandemic and...

April 5, 2022

Feature

180 Life Sciences focused on one of largest drivers of disease: inflammation

180 Life Sciences (NASDAQ:ATNF) has three families of novel biologic drugs in synchronized stages of development, addressing separate areas of inflammation, fibrosis and pain, for which there are no effective therapies.

March 29, 2022

Feature

First Wave developing targeted, non-systemic therapies for GI diseases

First Wave BioPharma (NASDAQ:FWBI) is advancing multiple clinical-stage programs built around its two proprietary technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and a...

March 22, 2022

Feature

Transforming biologic drug discovery with Sean McClain of Absci

As CEO and founder of Absci (NASDAQ:ABSI), a drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, Sean McClain has come a long way in the...

March 15, 2022

Feature

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with...

March 8, 2022

Feature

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

Precigen (NASDAQ:PGEN) is advancing a pipeline of next generation gene and cell therapies using precision technology in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

March 1, 2022

Rhythm Pharma targeting rare genetic diseases of obesity

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

TC Biopharm developing gamma-delta T-cells therapies for oncology

Aristea Therapeutics in four clinical trials in rare inflammatory diseases

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

NeuroSense advancing potential paradigm shift in ALS therapy

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

Synlogic advancing novel biotherapeutics based on synthetic biology

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

MindMed driving therapeutic potential of psychedelics for brain health disorders

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Qualigen advancing platform technologies in therapeutics and diagnostics

Talking mental health with Chris Wang of Shimmer

Claritas Pharmaceuticals transforming nitric oxide therapy

In conversation with Dr. Murat Kalayoglu of Cartesian

Cocrystal Pharma advancing programs in high-value antiviral drug targets

180 Life Sciences focused on one of largest drivers of disease: inflammation

First Wave developing targeted, non-systemic therapies for GI diseases

Transforming biologic drug discovery with Sean McClain of Absci

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

General

More